March 24, 2020 / 9:49 PM / 4 days ago

BRIEF-Allakos Announces Positive Phase 1 Results With Antolimab (Ak002) In Mast Cell Gastrointestinal Disease

March 24 (Reuters) - Allakos Inc:

* ALLAKOS ANNOUNCES POSITIVE PHASE 1 RESULTS WITH ANTOLIMAB (AK002) IN MAST CELL GASTROINTESTINAL DISEASE

* ALLAKOS INC - ANTOLIMAB (AK002) REDUCED GASTROINTESTINAL SYMPTOMS BY 64 PERCENT IN PATIENTS WITH MAST CELL GASTROINTESTINAL DISEASE

* ALLAKOS INC - FIVE OF SEVEN (71 PERCENT) PATIENTS HAD >50 PERCENT REDUCTION IN TSS-8.

* ALLAKOS INC - ANTOLIMAB WAS GENERALLY WELL TOLERATED AND NO DRUG-RELATED SERIOUS ADVERSE EVENTS OCCURRED DURING STUDY

* ALLAKOS INC - ALLAKOS IS CONDUCTING ADDITIONAL CLINICAL STUDIES TO BETTER CHARACTERIZE MGID Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below